)
Edge17 Oct 2025
A Castle in the Sky: The Story of Oracle
Oracle's journey from database innovator to disciplined enterprise backbone, now shaping the AI buildout with a standardized cloud infrastructure.
Aptose Biosciences (APTO) investor relations material
Aptose Biosciences Q2 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2025 earnings summary13 Aug, 2025
Executive summary
Tuspetinib-based triplet therapy in AML showed strong safety and efficacy, with dose escalation ongoing and no dose-limiting toxicities observed; multiple complete responses reported.
Luxeptinib development paused to prioritize tuspetinib due to funding constraints.
Company remains pre-revenue, focused on clinical development and reliant on external financing, with Hanmi providing a loan facility.
Financial highlights
Net loss for Q2 2025 was $7.0M, down from $7.3M in Q2 2024; six-month net loss $12.6M, down from $16.9M year-over-year.
Cash, cash equivalents, and restricted cash at $1.3M as of June 30, 2025, down from $6.7M at year-end 2024; company relies on Hanmi advances.
Research and development expenses decreased to $3.3M for Q2 2025 from $4.4M in Q2 2024; general and administrative expenses increased to $3.6M from $2.9M.
Operating expenses for Q2 2025 were $6.9M, compared to $7.3M in Q2 2024.
Negative working capital of $5.7M and shareholders' deficit of $14.4M as of June 30, 2025.
Outlook and guidance
Ongoing enrollment in the 160mg dose cohort for the TUSCANY trial; further data updates expected at upcoming conferences.
Plans to initiate Phase 2/3 pivotal program and select optimal tuspetinib dose for future trials.
Research and development expenses expected to be lower in 2025 unless new financing is secured; general and administrative expenses may increase slightly.
Company is exploring strategic alternatives and additional financing options, but faces significant uncertainty due to delisting from Nasdaq and market conditions.
Actively pursuing financing and cost reduction to extend cash runway.
Elaborate on financing and cost reduction efforts.
Why was APTO-253 development discontinued?
What is the status of the Ph 2/3 PIVOTAL program?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Aptose Biosciences earnings date
Q3 20257 Nov, 2025
Next Aptose Biosciences earnings date
Q3 20257 Nov, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Company Research17 Oct 2025
Beneath the Surface: A Conversation with Epiroc CEO Helena Hedblom
Legacy, innovation, and leading one of Sweden's most influential industrial companies into a new era.
)
Investor Relations14 Oct 2025
Boost Your Earnings Season Strategy With Real‑Time Alerts
Quartr Pro provides real time alerts, trend analysis and live coverage, giving analysts and investors instant insights to act faster in earnings.
Frequently asked questions
Aptose Biosciences Inc. is a clinical-stage biotechnology company focused on developing targeted therapies for hematologic malignancies, including leukemia, lymphoma, and myeloma. The company leverages innovative approaches in small-molecule drug design to address unmet medical needs in cancer treatment. The company is headquartered in Toronto, Canada, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage